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Abstract
Rapid mobilization of neutrophils from vasculature to the site of bacterial/viral infections and tissue injury is a critical step in
successful resolution of inflammation. The chemokine CXCL8 plays a central role in recruiting neutrophils. A characteristic
feature of CXCL8 is its ability to reversibly exist as both monomers and dimers, but whether both forms exist in vivo, and if
so, the relevance of each form for in vivo function is not known. In this study, using a ‘trapped’ non-associating monomer
and a non-dissociating dimer, we show that (i) wild type (WT) CXCL8 exists as both monomers and dimers, (ii) the in vivo
recruitment profiles of the monomer, dimer, and WT are distinctly different, and (iii) the dimer is essential for initial robust
recruitment and the WT is most active for sustained recruitment. Using a microfluidic device, we also observe that
recruitment is not only dependent on the total amount of CXCL8 but also on the steepness of the gradient, and the
gradients created by different CXCL8 variants elicit different neutrophil migratory responses. CXCL8 mediates its function by
binding to CXCR2 receptor on neutrophils and glycosaminoglycans (GAGs) on endothelial cells. On the basis of our data, we
propose that dynamic equilibrium between CXCL8 monomers and dimers and their differential binding to CXCR2 and GAGs
mediates and regulates in vivo neutrophil recruitment. Our finding that both CXCL8 monomer and dimer are functional in
vivo is novel, and indicates that the CXCL8 monomer-dimer equilibrium and neutrophil recruitment are intimately linked in
health and disease.
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Introduction
Cells interacting with pathogens in the vicinity of an infection or
injury produce small pro-inflammatory molecules called chemo-
kines, which attract and coordinate the movement of specific
leukocytes towards these sites [1,2]. The recruitment process
involves chemokines interacting with heparan sulfate and related
glycosaminoglycans (GAG) on the endothelial cells and in the
extracellular matrix to establish concentration gradients, and
activating G-protein coupled receptors (GPCR) on traveling
leukocytes to effect cell shape change and extravasation into the
tissue [3–5]. The leukocytes then travel to the site of infection,
destroy the pathogens, undergo apoptosis, and are phagocytosed
by tissue macrophages resulting in successful resolution of
inflammation [6].
Recruitment of circulating neutrophils to the site of infection is
the first line in host defense. Such a response should be immediate
and robust, yet controlled. Mechanisms that spatially and
temporally regulate neutrophil levels must exist in order to
minimize any collateral damage to healthy tissue. If this process is
not properly regulated, the infiltrating neutrophils not only kill
pathogens but also destroy host tissue, a hallmark of inflammatory
diseases [7].
CXCL8 (also known as interleukin-8), one of the best-
characterized members of the chemokine family, recruits neutro-
phils under such conditions as bacterial infection and tissue injury
[8]. During an inflammatory response, CXCL8 navigates through
different compartments from its point of production and is taken
up by venular endothelial cells abluminally and transcytosed to the
luminal surface, where CXCL8 is immobilized on endothelial cell-
surface GAGs for presentation to circulating neutrophils [9].
CXCL8 then provides directional cues by establishing a
concentration gradient, and guides neutrophils into the underlying
tissue. On reaching their destination, neutrophils augment the host
defense response by many mechanisms, including release of
proteases and reactive oxygen species. Clearly, multiple check-
points in trafficking neutrophils must exist, as an imbalance in the
recruitment process in terms of excess or reduced recruitment will
result in tissue damage and/or failed resolution of inflammation.
In this study, we show that the ability of CXCL8 to exist as
monomers and dimers and their differential activities act as one
such checkpoint.
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11754More than 40 chemokines have been identified in humans, and
structure determination and solution characterization have shown
that dimerization is a fundamental shared property by most, if not
all, chemokines. Most interestingly, chemokines show novel and
complex dimerization properties that set them apart from all
known proteins of similar size (MW,10 kDa). However, investi-
gating the activities of CXCL8 (or any chemokine) monomer and
dimer is not trivial as the very phenomenon of monomer-dimer
equilibrium prevents studying one species without interference
from the other. We circumvent this bottleneck by designing a
‘trapped’ non-associating CXCL8 monomer and a trapped non-
dissociating dimer, and have shown that the structures of the
trapped CXCL8 monomer and dimer are indistinguishable from
those of the native monomer and dimer; therefore their functions
should reflect those of the native monomer and dimer [10–13].
In this study, we have characterized neutrophil recruitment
profiles of the monomer, dimer, and wild type (WT) CXCL8 in a
mouse lung model. Our in vivo data show that WT exists as both
monomers and dimers, and that all three variants show distinctly
different recruitment profiles. At the highest dose tested, the dimer
shows the highest recruitment and was the most competent in
quickly mobilizing large quantities of neutrophils. On the other
hand, the monomer was less active and actually showed lower
recruitment at higher doses, but was active over longer time
periods. In contrast, recruitment by the WT was context
dependent – it showed properties resembling monomer, dimer,
or distinctly unique that could not be described as either solely due
to either monomer or dimer. The latter case was particularly
evident at later time points, where WT was most active, indicating
synergy between monomers and dimers. CXCL8 mediates its
function by binding to CXCR2 receptor on neutrophils and to
GAGs on endothelial cells. Our in vivo data reveal that differences
in recruitment profiles cannot be explained on the basis of receptor
affinities, suggesting that differences in GAG-binding and gradient
formation, in the context of the in vivo milieu, dictate the overall
recruitment. Our in vitro studies using a microfluidic device do
show that recruitment is not only dependent on the total amount
of CXCL8 but also on the steepness of the gradient. Our
observation that both CXCL8 monomer and dimer play distinctly
different in vivo roles is novel. We propose that CXCL8 monomer-
dimer equilibrium and neutrophil recruitment are intimately
linked in health and disease, and dysregulation in this process such
as permanently tipping the balance towards the dimeric or
monomeric form could trigger a ‘runaway’ inflammatory response
resulting in severe tissue injury or failed resolution of bacterial
infection leading to conditions such as sepsis.
Results
Recruitment by CXCL8 variants
In the current study, we have used our trapped CXCL8
monomer and dimer as surrogates to understand how the WT
monomer and dimer recruit neutrophils in vivo. The mouse lung is
a well-studied model for inflammation and infection. In order to
simulate the time course of an inflammatory response, we instilled
increasing doses of CXCL8 WT, trapped monomer, or trapped
dimer into the lung of BALB/c mice, and measured neutrophil
recruitment in the bronchoalveolar lavage fluid (BALF) at various
times. We initially characterized recruitment at 6 h, as the lifetime
of neutrophils is ,6 h after which they start to undergo apoptosis
and/or phagocytosed by macrophages. Our data showed that the
monomer and dimer have distinct neutrophil recruitment profiles,
and that their relative activities at various dosages can vary by
many orders of magnitude (Figure 1A–C; Figure S1). At the lowest
dose tested (0.1 mg/mouse), we observe that the trapped monomer
is active, and the trapped dimer is inactive (compared to the
control; p.0.05). When the dosage was increased to 1 mg/mouse,
recruitment by the monomer increases 20–30 fold compared to
the recruitment at 0.1 mg dose, while the dimer still remains
essentially inactive. The proportion of neutrophils compared to
total leukocytes also increases from ,20 to 80% for the monomer
at 1 mg, whereas it remains unchanged for the dimer (,4%). In
contrast, at the highest dose (10 mg/mouse), dimer is not only
active but also shows the highest levels of neutrophil recruitment,
and recruited ,12 fold more than monomer (p,0.001). Most
interestingly, monomer actually shows ,3 fold lower activity than
at the 1 mg dose (Figure 1D). The proportion of neutrophils is
.95% for the dimer and ,40% for the monomer. WT CXCL8
exhibits intermediate recruitment at all doses tested; behaving
more like the monomer at lower doses and like the dimer at higher
doses. The results obtained by the manual differential leukocyte
count were confirmed using fluorescence activated cell sorting
(FACS) (Figure 1E) and an MPO activity assay (Figure S2).
As the trapped dimer and the WT proteins are recombinantly
expressed, one concern was whether endotoxins and/or other
bacterial products present in our preparations contributed to
neutrophil recruitment. We carried out a number of control
experiments to eliminate this concern. We purified a known inactive
CXCL8mutant,R6K[14],usingthesameprotocolusedfortheWT
and trapped dimer, and tested for its ability to recruitneutrophils; we
observe this mutant to be completely inactive and incapable of any
recruitment (Figure 1F). We also measured the recruitment of a
chemically synthesized trapped dimer, and observed it to be similar
to that of the recombinantly expressed trapped dimer (not shown).
Additionally, we measured endotoxin levels using a commercially
available kit (ToxinSensor-LAL Endotoxin Assay, Genscript), and
did not detect any above the background. These observations
collectively indicate that all of the recruitment can be attributed to
different CXCL8 variants and not to spurious contaminants.
As CXCL8 variants at 10 mg dose showed a robust recruitment
response, we characterized the time course of neutrophil
recruitment for all variants at this dose. We observe that all three
variants show distinctly different recruitment profiles (Figure 2).
Whereas the recruitment by dimer is robust at 6 h, the levels drop
sharply and are much lower at later time points. On the other
hand, the recruitment by the monomer almost doubles at 12 h
compared to 6 h, and dips slightly at 18 h. Recruitment by the
WT is marginally higher at 12 h compared to 6 h, and shows
lower but nevertheless substantial recruitment at the 18 h time
point. Comparing recruitment at specific time points, we observe
that WT is significantly more potent compared to both monomer
and dimer at 12 and 18 h, and that the monomer shows relatively
low activity at all time points. These data provide critical insights
into temporal aspects of recruitment, and provide compelling
evidence that recruitment at any given time point is context
dependent, indicating that distinct recruitment profiles mediated
by different CXCL8 variants will influence the outcome of how
and whether inflammation will be resolved. Robust recruitment by
the dimer at the 6 h time point and overall low recruitment by the
monomer also indicate that recruitment is not correlated to
receptor binding affinities and that binding to GAG and gradient
formation most likely play a more prominent role.
Tissue trafficking of trapped CXCL8 variants
CXCL8 instilled intranasally enters alveolar spaces, and then
diffuses through lung tissue into the bloodstream. In order to
determine whether rates of CXCL8 trafficking could influence
recruitment, we determined CXCL8 levels in sera and BALF. Our
CXCL8 Structure-Function
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rapidly transported from the alveolar spaces into the lung tissue,
and CXCL8 levels are down to ,1 to 2% of the initial amounts at
the end of 12 h (Figure 3A). The data could be fitted to a simple
first order kinetic equation, and indicate that the dimer and the
WT are cleared from the BALF ,2 times more rapidly than the
monomer. On the other hand, we observe a more complex
temporal distribution in the serum (Figure 3B). We observe the
presence of all variants at the very first time point of 15 mins.
However, the highest serum level is observed for the monomer at
4 h, and at this time point, dimer levels are already significantly
low, and remain low for the later time points. The levels of
monomer and WT rapidly fall by 6 h, and are barely detectable
for the subsequent time points. If total amount of CXCL8 directly
correlates with neutrophil recruitment, the chemokine levels at 4
to 6 h should be responsible for the recruitment seen at 12 h, and
levels at 12 h for recruitment seen at 18 h. The higher levels seen
for the monomer and the WT at 4 h crudely correlates with
recruitment seen for 12 h, but there is no correlation with low
CXCL8 levels at 12 h and recruitment at 18 h. These observa-
tions suggest that other factors besides absolute levels of soluble
chemokine, such as the presence of a GAG-immobilized
chemokine gradient, mediate overall recruitment.
Expression of endogenous mouse cytokines and
chemokines
During the process of trafficking and in the target tissue, the first
wave of neutrophils trigger expression of a wide variety of
molecules including expression of cytokines and chemokines.
These cytokines/chemokines could recruit more neutrophils and/
or recruit other leukocytes such as monocytes. It is known that
monocytes are recruited as the second wave, and that these
monocytes play a critical role in phagocytosing apoptotic
neutrophils, and are needed for successful resolution of inflam-
mation [15,16]. Therefore, we measured the levels of the following
mouse cytokines (IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9,
IL-10, IL-12(p70), IL-12(p40), IL-13, IL-17, G-CSF, GM-CSF,
IFN-c) and chemokines (MCP-1, MIP-1a, MIP-1b, KC, eotaxin,
and RANTES) in the BALF at different times post-inoculation
with the dimer, which shows robust recruitment, and the R6K
mutant, which shows no recruitment.
Mouse chemokines and cytokines were not elevated for 0.1 and
1 mg doses at any time point and for the 10 mg dose at 12 and 18 h
time points (data not shown).However, significant expressionof KC
was observed for the 10 mg dose at 2 and 6 h time point for the
dimer, and unexpectedly,alsofortheR6Kmutant(Figure 4).Asthe
R6K mutant is inactive for CXCR2 receptor activation and does
Figure 1. Neutrophil recruitment at 6 hours post-inoculation of various doses of CXCL8 variants. (A) Neutrophil recruitment by CXCL8
monomer, dimer, and wild type (WT) variants for 0.1, 1.0, and 10.0 mg doses. Bronchoalveolar lavage fluid (BALF) samples from mice treated with
CXCL8 variants were processed as described in Methods. Each data set represents an average of 2–3 experiments using 4–6 animals/group. P,0.05
between monomer and dimer, monomer and WT and dimer and WT at all doses. (B–C) Neutrophil levels for 0.1 mg and 1 mg doses are shown on an
expanded scale to highlight the differences in neutrophil recruitment among the different CXCL8 variants. (D) Profile of neutrophil recruitment by
monomer at various doses. (E) Estimation of neutrophil levels using fluorescence-activated cell sorting (FACS). Representative data of neutrophil
recruitment in lungs for the 10 mg dose are shown. BALF cells were stained with neutrophil specific Gr-1 antibody conjugated with a fluorescent dye
phycoerythrin (PE). (F) Neutrophil recruitment by the inactive R6K CXCL8 mutant is negligible, and similar to the control. The inset shows levels of R6K
and control recruitment on an expanded scale for better clarity. Statistical analyses were carried out using ANOVA (Graph Pad prism 4); p,0.05
between monomer and dimer, monomer and WT, and dimer and WT at all doses, and more significant if so indicated (***p,0.001).
doi:10.1371/journal.pone.0011754.g001
CXCL8 Structure-Function
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activation of a non-canonical receptor in one or more cell types in
the lung. Other chemokines have been shown to activate receptors
such as tyrosine kinases, but our data show such activation and
subsequent signaling events play no role in neutrophil recruitment.
We also observed increased levels of the cytokines G-CSF and, to a
smaller extent, IL-6, for both the dimer and the R6K inactive
mutant, indicating once again that the increased expression of these
cytokines/chemokines play no role in neutrophil recruitment.
The observation that there is no correlation between endoge-
nous mouse cytokine/chemokine levels and neutrophil recruit-
ment suggest that CXCL8 continues to play a role in recruitment
though the actual CXCL8 levels are barely detectable at 6 h. This
could mean that CXCL8 is mostly immobilized and so could not
Figure 2. Temporal variation in neutrophil recruitment. (A) Neutrophil recruitment by CXCL8 monomer, dimer, and WT variants for the 10 mg
dose at different time points. For clarity, recruitment by the individual variants is shown in panels B, C, and D. BAL samples were processed as
described in Methods. Each data set represents an average of two experiments using 4–6 animals/group.
doi:10.1371/journal.pone.0011754.g002
Figure 3. Trafficking of CXCL8 in mouse lung. Levels of CXCL8 WT (grey), monomer (black), and dimer (white) were measured in BAL (A) and
serum (B) using ELISA, at different time points post-inoculation in the mouse lung. Monomeric CXCL8 shows higher serum levels (evident at the 4 h
time point) than WT or trapped dimer.
doi:10.1371/journal.pone.0011754.g003
CXCL8 Structure-Function
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time points has set the molecular machinery in place for
subsequent overall recruitment. For instance, we observe signif-
icant levels of neutrophils in the lung tissue at 6 hrs that would
eventually travel into the alveolar spaces and be detected in BALF
at later time points.
Unlike monocytes, neutrophils once in the tissue are not known
to traffic back into circulation and are believed to undergo
apoptosis and/or phagocytosed by monocytes. The relatively
higher levels of neutrophils for the monomer and WT at 12 h
indicate that the rate of neutrophil trafficking from vasculature to
the tissue are different for the monomer and dimer. The dimer
seems to mobilize neutrophils quickly and efficiently whereas
mobilization by the monomer is more persistent though at lower
levels over a longer period of time.
Inflammatory Response and Tissue Damage
To understand the consequence of increased neutrophil
recruitment into the lung, we compared the histopathology of
lung tissue of CXCL8 dimer-treated mice after 6 h and those
infected with human metapneumovirus (hMPV), a respiratory
virus that induces lung injury in infected mice after 24 h [15].
Whereas, hMPV-infected mice show evidence of damage such as
airway obliteration, extensive peribronchiolar and perivascular
inflammatory cell accumulation (Figure 5), CXCL8-treated mice
were observed to be no different from the control.
We also measured total protein levels in BAL, as acute lung
injury and tissue damage causes influx of protein into the air
spaces as a consequence of increased permeability of the alveolar–
capillary barrier. CXCL8-treated mice showed ,2-fold increase in
total protein for all variants at 6 h which remained essentially the
same over 18 h (Figure 5D). These data indicate minimal or no
neutrophil-mediated injury, and further, mice were completely
healthy and showed no weight loss or other signs of stress
emphasizing that these experiments mimic a proinflammatory
response.
Resolution of inflammation
To understand how inflammation is resolved, we characterized
neutrophil and monocyte levels over a period of 72 h in mice
treated with 10 mg of CXCL8 dimer. We observed that neutrophil
levels are maximal at 6 h and then drop dramatically. On the
other hand, the alveolar monocyte numbers initially decreased up
to 6 h and then continued to increase up to 72 h, and showed
extensive phagocytosis of neutrophils at 24–48 h indicating
resolution of inflammation (Figure 6A–B). It is well established
Figure 4. Expression of endogenous mouse chemokines and
cytokines. Cell-free supernatants of BAL from mice treated with CXCL8
variants were analyzed for mouse cytokines and chemokines at
different time points. Representative data of GCSF, KC and IL-6 levels
from mice treated with 10 mg of trapped dimer (which shows robust
recruitment) and R6K mutant (inactive, no recruitment) are shown for 2
and 6 h time points. No correlation is seen between KC levels and
neutrophil recruitment profiles.
doi:10.1371/journal.pone.0011754.g004
Figure 5. Tissue damage due to CXCL8-mediated neutrophil
influx. Representative lung sections of mice treated with (A) 50 ml
phosphate buffer saline (PBS), (B) 10 mg CXCL8 dimer in 50 ml PBS after
6 h, and (C) 10
7 PFU of human metapneumovirus in 50 ml PBS after
24 h. Lungs were fixed with 10% formaldehyde in PBS, and histological
sections were stained with haematoxylin and eosin (206magnification;
scale bar=200 mm). Markers of tissue damage such as airway
obliteration (arrow heads), peribronchiolar (short arrow), and perivas-
cular (long arrow) inflammatory cell accumulation are obvious in the
virus-infected lung tissue, and are completely absent in CXCL8 dimer
treated lung tissue. (D) Total protein in cell free BALF from mice treated
with 10 mg of CXCL8 WT, trapped monomer at various time intervals.
Statistical analyses show no significant differences in protein levels
among different CXCL8 variants at all time points.
doi:10.1371/journal.pone.0011754.g005
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monocytes, and that these monocytes and monocyte-derived cells
undergo apoptosis and also emigrate through lymph nodes [16].
Interestingly, we also observed these monocytes/macrophages
undergoing mitosis during this time period (Figure 6C). Though
macrophages are differentiated cells, there is evidence that they
can undergo mitosis [17], and that the overall increase in
monocyte population is due to both trafficking in and out of the
tissue and cell division.
Chemotaxis using a microfluidic device
To understand the mechanisms underlying how monomers and
dimers mediate recruitment, we measured the chemotactic activity
of our trapped monomer, dimer, and the WT for CXCR2
expressed in HL60 cells using a microfluidic chamber that allows
control of both the steepness of the chemokine gradient and
protein concentration [18] (Figures 7A–B; supplemental Videos S1
and S2). Monomer and WT CXCL8 are minimally active and the
dimer is inactive under conditions of a shallow gradient and low
chemokine concentration (0–1 nM). In contrast, both monomer
and WT are maximally active under conditions of a steep gradient
and low chemokine concentration (0–10 nM). At these concen-
trations, WT exists predominantly as a monomer, so it is not
surprising that WT behaves like the monomer. Under conditions
of a steep gradient and high chemokine concentration (10–
100 nM), only the dimer is active while both the monomer and the
WT are inactive. Lack of activity for both the monomer and the
WT was unexpected. Interestingly, under conditions of interme-
diate gradient and high chemokine concentration (10–50 nM),
dimer is less active, monomer is more active, and the WT remains
inactive. The activity (or lack thereof) of the WT activity cannot be
explained simply as sum of monomer and dimer activities
indicating that chemotaxis is mediated by a combination of
monomer/dimer ratio, total local concentration, and the steepness
of the gradient. Our microfluidic assay recreates a gradient under
soluble flow conditions, and any immobilization of chemokine
occurs on precoated fibronectin and not on GAGs. Binding to
fibronectin is not the same as GAGs, and this may also account for
discrepancies between in vivo and in vitro activities of our variants.
Nevertheless, we observe that our in vitro chemotaxis measure-
ments of monomer and dimer correlate with some, but not all, of
our in vivo observations. The most important observation from
Figure 6. Resolution of Inflammation. (A) Monocyte and neutrophil levels in BALF of mice treated with 10 mg of dimer over a period of 72 h.
Dynamics of alveolar monocytes and neutrophil levels indicate resolution of the inflammation. (B) Phagocytosis of neutrophils by monocytes (arrow)
from mice treated with 10 mg dose of trapped dimer for 24 h. (C) Alveolar monocytes in various stages of mitosis are seen in BALF of mice treated
with 10 mg dose of trapped dimer for 48 h. The observed cell division could explain the increase in monocytes numbers observed. Scale bar=20 mm.
doi:10.1371/journal.pone.0011754.g006
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translate to more robust chemotaxis. Low levels of chemotaxis and
lack of recruitment for the dimer observed for shallow gradient
and low concentration reflect the in vivo response to the 0.1 mg
dose. Robust chemotaxis observed for the dimer at steep gradient
and high concentration reflect recruitment observed for the 10 mg
dimer at the 6 hr time point.
Discussion
CXCL8 function in vivo is dictated by many factors, and most
importantly, will be modulated by variations in its concentrations.
Under conditions of active neutrophil recruitment, local in vivo
CXCL8 concentrations will vary by many orders of magnitude,
and so at any given time and place, it could exist as a monomer,
dimer, or both. CXCL8 was the first chemokine to be discovered
and characterized [19], and was initially thought to be active as a
dimer as structural studies revealed CXCL8 to be a dimer [20].
Indeed, most early structural studies of various chemokines
indicated that they exist as dimers and tetramers [21,22]. CXCL8
binds its receptors with nanomolar (nM) affinity, and we had
shown that a trapped CXCL8 monomer and WT CXCL8 have
similar receptor binding activities [10]. It is now known that WT
CXCL8 dimer dissociates at mM concentrations, and so it is not
surprising that it is monomeric at nanomolar concentrations used
in in vitro functional studies and dimeric at millimolar concentra-
tions used in structural studies [23]. However, these studies do not
rule out the possibility that dimer could bind and activate the
receptor, and therefore knowledge of receptor-binding character-
istics of the dimer is also essential.
To better understand the role of monomers and dimers in
receptor activation, we recently characterized the functional
responses of our trapped monomer, trapped dimer, and WT in
mammalian cells individually expressing CXCR1 or CXCR2
[13]. We observe the dimer binds CXCR2 receptor with lower
affinity and is less active for functions such as endocytosis and as
active as the monomer for functions such as receptor phosphor-
ylation and internalization. In contrast, the monomer, compared
to the dimer, binds CXCR1 with higher affinity and is more active
for all functional activities. Unlike human neutrophils that express
both receptors, mouse neutrophils seem to express only the
CXCR2 receptor. Various studies have shown that mouse does
code for the CXCR1 receptor as evident from mRNA expression,
but at this time, there is no evidence for expression of a functional
CXCR1 receptor in mouse neutrophils [24–26]. Moreover,
neutrophils isolated from CXCR2 knockout mouse show no
chemotactic activity to both human and mouse chemokines [27],
and CXCR2-specific inhibitor significantly reduces neutrophil
recruitment in a number of mouse disease models [28–30]. These
observations together suggest that CXCR2 predominantly medi-
ates neutrophil receptor function.
Sequence and functional analysis indicate that both human and
mouse express a number of neutrophil-activating chemokines. All
share considerable sequence homology, have the characteristic
ELR motif in the N-terminus, and show robust in vitro activity to
both human and mouse CXCR2 expressed in mammalian cell
lines. Interestingly, a mouse equivalent of CXCL8 does not exist as
none of the mouse ELR-chemokines show robust activity for either
human or mouse CXCR1, and it has been proposed that GCP-2/
CXCL6 fulfils this role in mice [26].
CXCL8 function also involves binding to GAG on endothelial
cells and the extracellular matrix, and there is evidence from in vitro
and knockout animal model studies that GAG-binding promotes
and facilitates formation of a concentration gradient, which is
essential for directional neutrophil recruitment [31,32]. Further, in
vitro and ex vivo studies have shown that GAG binding and
dimerization are coupled, and that the dimer binds GAGs with
higher affinity [33–35]. In vitro functional measurements are
carried out under controlled and steady state conditions using
defined concentrations, whereas in vivo conditions are more
complex with concentrations that could vary by many order of
magnitude spatially and temporally, and so correlating in vitro
observations to in vivo directional neutrophil recruitment is not
trivial. Indeed, experiments using microfluidic device that allow
varying CXCL8 gradients and concentrations show complex
chemotaxis profiles (Figure 7).
Studying the in vivo roles of WT monomer and WT dimer is not
feasible as the relative proportions of monomer and dimer will
vary temporally and spatially, and moreover, no techniques exist
to continuously monitor the levels of the two forms. In this study,
we circumvent these roadblocks, by carrying out in vivo animal
model studies using our trapped non-associating monomer and
non-dissociating dimer. We observe that recruitment is context
dependent, and recruitment at any given time point and dose is a
snap shot but is a culmination of all events from the time point of
administering CXCL8. We observe that the dimer is the most
potent form for eliciting robust neutrophil recruitment, that the
monomer is less potent and shows low sustained recruitment, and
that the WT alone shows sustained and steady levels of
recruitment, indicating a fundamental role for monomers and
dimers in regulating recruitment (Figures 1 and 2). These
observations are unprecedented, and could not have been
predicted on the basis of in vitro functional assays.
On the basis of our current studies, we discuss possible
mechanisms of how CXCL8 recruits neutrophils (Figure 8). Our
in vitro studies using the microfluidic device and our in vivo animal
studies show that recruitment is not only dependent on the total
amount of CXCL8, but also on the steepness of the gradient,
which in turn is dependent on the continuous inter-conversion
among various forms of CXCL8: free monomer and dimer and
GAG-bound monomer and dimer. We observe that the ability of
monomers and dimers to reach the blood stream is not limiting,
and that their levels spike at different times, and also fall quickly
indicating rapid clearance (Figure 3). Most importantly, we
observe that there is no simple correlation between serum levels
and extent of recruitment, indicating that receptor and GAG
binding properties play a prominent role in regulating recruit-
ment.
Robust recruitment by the dimer at 6 h cannot be explained on
the basis of receptor binding affinity or activity alone, as dimer is
equally or less active than monomer in all functional assays [13].
Lower recruitment by the monomer at the 6 h time point
Figure 7. Chemotactic activity of CXCL8 variants. (A) Chemotaxis of dHL60-CXCR2 cells, in response to gradients of CXCL8 variants, was
measured in the microfluidic gradient chambers. Chemotaxis for all variants was measured as a function of both varying steepness and
concentration. The data are shown as the mean chemotactic index (C.I.), which is defined as the displacement of cells that move along the Y-axis
(direction of gradient) divided by the total migration distance. Statistical analyses were performed with two-way ANOVA with Bonferroni posttests,
*p,0.05; ***p,0.001. (B) Movement tracks of ten randomly picked cells in response to different concentration gradients of CXCL8 variants. Gradients
of monomer, dimer or WT CXCL8 were delivered into the device by a constant flow (the direction shown by the arrow). The cell movements
(Supplemental Videos S1 and S2) were recorded every 20 sec for 30 min and data were analyzed with Metamorph software.
doi:10.1371/journal.pone.0011754.g007
CXCL8 Structure-Function
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receptor affinity, as monomer is actually the high-affinity ligand
[10]. Lower recruitment by the monomer at the 10 mg dose
compared to the 1 mg dose also cannot be explained by receptor
binding affinity (Figure 1). Therefore, interactions with GAG and
gradient formation most likely play a more prominent role, with
non-optimal gradients at higher concentrations leading to lower
recruitment (data for the 10 mg dose at 6 h) and optimal gradients
at lower concentrations leading to higher recruitment (data for the
1 mg dose for 12 h). It is also possible that the high levels of soluble
monomer desensitize the receptor resulting in poor recruitment. In
this case, ligand binding results in internalization of the ligand-
receptor complex, proteolysis of the ligand, and eventual recycling
of the receptor to the surface [13,36]. Attenuation of recruitment
has been observed in various studies where CXCL8 was
systemically administered [37,38]. It is likely that local adminis-
tration of CXCL8 leads to spatially and temporally controlled
gradient formation, conditions that favor directed neutrophil
recruitment, whereas systemic administration results in quick
uniform distribution and high soluble chemokine levels in the
blood, conditions that disfavor directed neutrophil recruitment.
It is now thought that GAG-bound CXCL8 on the luminal
endothelial surface forms a haptotactic gradient, which functions
as a directional cue for recruiting neutrophils into the tissue [39]. It
has been argued that soluble chemokine gradients are unlikely to
exist, as they would be washed away with the blood flow.
Nevertheless, soluble chemokine must exist due to the intrinsic
equilibrium between the GAG-bound and the free forms. In
principle, GAG-bound monomer and dimer, besides soluble
monomer and dimer, can also bind and activate neutrophil
receptors. This could be particularly relevant in the context of in
vivo milieu due to high occupancy of the GAGs at high dimer
concentrations. The only studies on GAG-bound chemokine in
which CXCL8 activity was measured with and without adding
soluble GAG in cell-based assays were inconclusive and contra-
dictory with one study showing soluble GAG enhances CXCL8
binding and the other showing reduced binding [40,41]. We
propose GAG-bound CXCL8 dimer plays an important role in
regulating the local CXCL8 concentration by functioning as a
reservoir, and regulating soluble CXCL8 concentration for
engagement with the receptor. It is essential to remember that
this scenario applies only for WT dimer and not for trapped dimer.
The WT dimer in the free form can dissociate to monomers and so
recruit whereas the trapped dimer will not and is inactive below a
threshold concentration, as reflected by its lack of activity at low
doses and low activity at 12 and 18 hr time points (Figure 2).
Our data from the WT show that the ability to interchangeably
exist as both monomers and dimers is essential for sustained
recruitment. This is particularly evident when we correlate the
recruitment at different dosages to the temporal profile of
neutrophil recruitment (Figures 1 and 2). As the trapped monomer
demonstrates, if WT CXCL8 did not dimerize, its recruitment
though sustained would remain low. Such low levels of
recruitment may not be sufficient in destroying pathogens in a
timely and efficient manner that could be critical for successful
resolution of inflammation. On the other hand, if WT CXCL8
exists only as a dimer, its recruitment would be robust above a
concentration threshold and essentially ineffective below this
threshold. These observations suggest that monomer alone cannot
sustain sufficient neutrophil recruitment, and so dimerization acts
as an ‘on’ switch triggering the large neutrophil influx that is
essential for combating infection. However, persistent high dimer
levels for extended period of time is not desirable as it could elicit a
runaway inflammatory response. Data for WT CXCL8 shows
Figure 8. A schematic showing processes involved in neutrophil recruitment in lung tissue. CXCL8 produced at the site of insult migrates
to the bloodstream where they form a concentration gradient, made up of monomers and dimers in solution, and monomers and dimers bound to
GAGs. Free and GAG-bound monomers and dimers exist in equilibrium, and each species can bind and activate cognate receptors on neutrophils.
Local concentrations and gradients dictate the spatial and temporal predominance of each species, which in turn modulates overall recruitment.
doi:10.1371/journal.pone.0011754.g008
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monomers and dimers regulate recruitment. We propose that
the ability of CXCL8 to continuously redistribute between free-
and cell-bound dimers monomers and dimers is essential for
orchestrating immediate, directed, sustained, and controlled
neutrophil recruitment for a healthy proinflammatory response.
A schematic showing different forms of CXCL8 and their
interactions for neutrophil recruitment is shown in Figure 8.
In a true disease situation, the process of resolution of
inflammation is more complex due to continuous chemokine
production and neutrophil recruitment that could last over a
longer period. Nevertheless, our recruitment data from all of the
CXCL8 variants at different doses and time points have given
snapshots of how monomers and dimers and their equilibrium
bring about resolution of inflammation. The level and duration of
proinflammatory response needed would depend on the severity of
infection. Accordingly, the amount of CXCL8 expressed could be
low or high. Severe infection demands immediate response and
would result in higher levels of CXCL8 expression, and is best
represented by profiles seen for the 10 mg dose. Neutrophil levels
observed at 6 h for the dimer are comparable to those observed in
animal disease models, indicating an obligatory role for CXCL8
dimerization. Low levels of expression would essentially result only
in monomers, resulting in low but sustained neutrophil recruit-
ment and eventual resolution of inflammation. Recruitment
profiles observed for the 0.1 and 1 mg doses could reflect such a
scenario. On the other hand, low levels of recruitment in the
course of severe infection would indicate a dysregulation in
chemokine expression, and if unchecked could result in significant
morbidity and mortality.
Our observation that both CXCL8 monomers and dimers can
actively recruit is novel, and different from what has been observed
for other chemokines. Although CXC and CC monomers are
structurally similar, CXC and CC dimer structures are different as
they dimerize using different regions of the protein, and oligomers
show structural properties of both CXC dimers and CC dimers
suggesting that the molecular mechanisms by which any given
chemokine recruits leukocytes are likely to be different. For
instance, CXC chemokine SDF-1a/CXCL12 that dimerizes like
CXCL8 shows functional properties distinctly different from
CXCL8. In contrast to our observation, a disulfide-linked
CXCL12 was shown not capable of chemotaxis [42]. CXC
chemokine IP-10/CXCL10 forms dimers and oligomers, and a
trapped CXCL10 monomer was shown to be inactive in an in vivo
mouse lung model [43]. Monomeric and GAG-binding-deficient
mutants of CC chemokines RANTES/CCL5, MIP-1b/CCL4,
and MCP-1/CCL2 are inactive in the mouse peritoneum model
[44], and a trapped CC MIP-1b dimer has been shown incapable
of binding its receptor [45]. These observations suggest that
dimerization of CC chemokines is essential only for GAG-related
function and monomers are essential only for GPCR-related
function. Compelling evidence for in vivo dimer function also
comes from a recent study that has shown CCL5 and CXCL4
form heterodimers, and design of peptides that disrupt this
interaction inhibit atherosclerosis in hyperlipidemic mice [46]. We
propose chemokines have evolved to exploit the property of
reversibly existing as monomers, dimers, and higher order
oligomers as a means to regulate a wide variety of physiological
functions. This on/off switch offers the advantage of not requiring
additional accessory proteins such as kinases for phosphorylation,
and so can confer an advantage for fine-tuning spatial and
temporal regulation that may not be otherwise possible.
In summary, our results from different dosages and recruitment
levels at different time points for the monomer, dimer, and the
WT have provided valuable snapshots on the mechanisms and the
interrelationship between monomer-dimer equilibrium, differen-
tial binding affinities and activities for GAG and CXCR2 receptor,
gradient formation, and recruitment and activation at the site of
infection, and successful resolution of inflammation. In particular,
we show that robust neutrophil recruitment requires CXCL8
dimerization, and that the ability of CXCL8 to reversibly exist as
monomers and dimers and GAG binding-mediated gradient
formation play critical roles in regulating neutrophil recruitment.
Recruitment could also involve other interactions such as binding
to non-canonical receptors, non-signaling chemokine receptor
DARC, or proteolysis by leukocyte-released proteases [47–49].
DARC receptors expressed on erythrocytes and also on endothe-
lial cells have been shown to function as sinks and so could
differentially regulate recruitment [48]. However, their role in the
context of monomers and dimers remain to be studied.
Dysregulation in neutrophil recruitment and activation results in
a wide variety of inflammatory diseases, and so considerable
interest exists for designing drugs that could inhibit this process.
We propose infection or injury triggers continuous chemokine
production, tipping the monomer-dimer equilibrium in favor of
dimer. The predominance of dimer results in persistent neutrophil
infiltration, which in turn leads to acute or chronic inflammation
and tissue injury. Therefore, design of small molecules that inhibit
CXCL8 dimerization could function as drugs for a wide variety of
neutrophil-mediated inflammatory diseases.
Materials and Methods
Ethics Statement
Mice were maintained in pathogen-free conditions in the animal
research facility (ARC) of UTMB, in accordance with the NIH
and UTMB institutional guidelines for animal care. Cages,
bedding, food and water are sterilized before use. All animal
work was approved by Institutional Animal Care and Use
Committee (approval number – 0702005).
Design and Synthesis of human CXCL8 variants
The trapped human CXCL8 monomer (L25NMe) was
designed by substituting the dimer interface residue Leu-25 with
N-Methyl Leu, which disrupts H-bonding interactions and
introduces steric bulk about the two-fold symmetry point
[10,11]. The trapped human CXCL8 dimer (R26C) was designed
by mutating Arg-26 at the dimer interface to Cys-26. This results
in a disulfide bridge formation between two monomers in the
dimer [12]. L25NMe was chemically synthesized, and the wild
type (WT), trapped dimer R26C, and the inactive R6K mutant
were recombinantly expressed.
In vivo recruitment in a mouse lung model
Female, 8- to 10-week-old BALB/c mice purchased from
Harlan (Houston, TX) were housed under specific pathogen-free
conditions in the animal research facility of University of Texas
Medical Branch (UTMB), in accordance with the National
Institutes of Health and UTMB guidelines for animal care. Under
light anesthesia, mice were inoculated intranasally with 0.1, 1 or
10 mg of CXCL8 variants in Dulbecco’s phosphate-buffered saline
(D-PBS) in a 50 ml volume [50]. Control mice were inoculated
with the same volume of D-PBS. At various time points post-
inoculation, mice were injected intraperitoneally with a mixture of
ketamine and xylazine, and sacrificed by exsanguination via
femoral vein puncture. The BALF was collected by flushing lungs
three times with 1 ml of ice-cold DPBS. BALF from each animal
were pooled and centrifuged at 4uC for 5 mins at 13,000 rpm, and
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for cytospin slides and total leukocyte counts. Cytospin slides of
BALF were prepared (Shandon, Thermo Electron Corporation;
5 mins at 800 rpm), fixed and stained with hematoxylin and eosin,
and a differential leukocyte count was performed. For total
leukocyte determination, BALF samples were diluted with Turk
blood diluting fluid (Ricca chemical, TX) to lyse RBCs and then
the total cells were counted using a hemocytometer.
For estimating neutrophils by FACS, cells were stained with a
neutrophil-specific fluorescently labeled antibody against the
murine myeloid differentiation antigen Gr-1 (RB6-8C5, PharMin-
gen), and analyzed with a FACScan flow cytometer equipped with
CellQuest software (Becton Dickinson).
For estimating neutrophils by myeloperoxidase (MPO) assay,
cells from BAL fluid were resuspended in 50 mM phosphate buffer
(pH 6.0) containing 0.5% hexadecyltrimethylammonium bromide
(HTAB), sonicated, centrifuged, and the supernatants were tested
for MPO activity using o-dianisidine (Sigma) and H2O2 as
substrates. The change in absorbance at A460 was measured at
1 min intervals for 7–8 min. One unit of MPO activity is defined
as the amount of enzyme which degrades 1 mmol of H2O2/min at
25uC.
Estimation of CXCL8 levels using ELISA
Tissue trafficking of CXCL8 WT, trapped monomer, and
trapped dimer were analyzed in the lung model. BAL, lung, and
serum samples were analyzed using ELISA. CXCL8 levels in
BAL, serum, and lung tissue samples were measured immediately
after thawing and appropriate dilution in HBSS, using the IL-8/
CXCL8 DuoSet ELISA Kit (R&D Systems, Minneapolis, MN).
CXCL8 levels were normalized to initial levels (total levels in BAL,
lung and serum, measured immediately after inoculation, equals
100%) for each CXCL8 variant, and plotted as a function of time.
Mouse cytokine/chemokine analysis
The cell-free supernatants, collected and stored at 270uCa s
described above, were thawed to room temperature and tested for
various mouse cytokines and chemokines using the Bio-Plex
Mouse Cytokine 23-Plex panel (Bio-Rad Laboratories, Hercules,
CA), according to the manufacturer’s instructions. All of the
cytokines/chemokines were assayed using BALF from at least two
sets of mice each containing three to four different animals for any
given dose and time point. The reported values are the average of
all the values.
Protein estimation
Total protein in BAL supernatants was estimated by the BCA
assay using the BCA protein assay kit (Thermo Fisher Scientific
Inc., Rockford, IL, USA) following the manufacturer’s instruc-
tions.
Chemotaxis assays using microfluidic device
Human promyelocytic HL-60 cells stably transfected with the
CXCR2 plasmid were used for the chemotaxis assays. The HL-60
cells were differentiated by adding 1.25% dimethylsulfoxide
(DMSO) to the cell suspension, and differentiation was evaluated
by observing morphological changes evident 6–7 days after
DMSO addition. The microfluidic chemotaxis device used in this
study was especially designed to establish a stable and uniform
chemokine concentration gradient [18]. The cells were monitored
by time lapse imaging with a Hamamatsu digital camera using
MetaMorphH software (Molecular Devices Corporation, Down-
ingtown, PA) on a Zeiss Axiovert 200M inverted microscope (Carl
Zeiss MicroImaging, Inc, Thornwood, NY), with images obtained
at 20 sec intervals for 30 mins. The images obtained were
analyzed using MetaMorphH software.
Statistics. All results unless specified otherwise are shown as
mean and standard deviation from the mean. Differences were
considered significant at p,0.05. All experiments were repeated at
least three times. Statistical analyses were carried out using
ANOVA (Graph Pad prism 4).
Supporting Information
Figure S1 Estimation of neutrophil levels in the lung Broncheo-
alveolar lavage fluid (BALF). BAL neutrophils (N) and macro-
phages (M) as seen in cytospin slides stained with hematoxylin and
eosin (H&E), obtained from mice treated with PBS (control),
CXCL8 wild type (WT), trapped monomer and trapped dimer.
Scale Bar, 20 mm.
Found at: doi:10.1371/journal.pone.0011754.s001 (1.85 MB
DOC)
Figure S2 Estimation of neutrophil levels in the BALF using
MPO assay. MPO is a neutrophil granule enzyme and its activity
has been shown to correlate with neutrophil levels. Measured
neutrophil levels are similar to those measured from differential
counting (Fig. 1A). P is at least ,0.01 between monomer and
dimer, monomer and WT, and dimer and WT at all doses. Each
data set represents an average of 2–3 experiments using 4–6
animals/group. Statistical analyses were carried out using
ANOVA (Graph Pad prism 4).
Found at: doi:10.1371/journal.pone.0011754.s002 (0.18 MB
DOC)
Video S1 A video file showing neutrophil chemotaxis for the
monomer.
Found at: doi:10.1371/journal.pone.0011754.s003 (5.81 MB
MOV)
Video S2 A video file showing neutrophil chemotaxis for the
dimer.
Found at: doi:10.1371/journal.pone.0011754.s004 (2.57 MB
MOV)
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